CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
ponatinib hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02272998
NCT02272998Phase 2Completed
CompareCT.gov

Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

Sameek Roychowdhury·interventional·Posted Oct 23, 2014·Updated Mar 24, 2025

In Brief

A Phase 2 clinical trial evaluating ponatinib hydrochloride and laboratory biomarker analysis for Malignant Neoplasm. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several alterations, or mutations, in its deoxyribonucleic acid (DNA) sequence. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether a patient's genetic alterations may affect how well ponatinib hydrochloride works.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 23, 2014
Enrollment StartFeb 24, 2015
Primary CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 11.7 years ago

Interventions

ponatinib hydrochloridedrug

Given PO

laboratory biomarker analysisother

Correlative studies